Table 2 Therapy data
From: Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer
Surgery and concomitant therapy | ||
|---|---|---|
| Â | n | % |
Patients with incomplete (primary) surgery | 4 | 10.3 |
Patients with surgical nodal staging | 11 | 28.2 |
Clinical nodal staging | 28 | 71.8 |
Complete chemotherapy (Cisplatin 40Â mg/m2 weekly) | 31 | 79.5 |
Patients without all cycles of chemotherapy due to hematological toxicities | 3 | 7.7 |
Patients without chemotherapy due to contraindication or refusal | 5 | 12.8 |
Radiotherapy dosage | ||
| Â | Median (Gy) | Range (Gy) |
Radiotherapy duration (days) | 60 | 46 - 96 |
EBRT elective pelvic nodal dose (Gy) | 50.4 | 45-55.8 |
EBRT elective paraaortral dose (Gy) | 47.7 | 45 - 50.4 |
EBRT Tumor Boost dose (Gy) | 9 | 5.4 - 21.6 |
EBRT Total Tumor Dose (Gy) | 59.4 | 50.4 - 72 |
LN Boost dose (Gy) | 62 | 59.4 - 64.8 |
Brachytherapy total dose (Gy) | 18 | 10 - 24 |
Brachytherapy single dose (Gy) | 6 | 5-6 |